Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)

This investigation is for anyone who acquired securities in Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) prior to November 3, 2026.

The Law Offices of Howard G. Smith believes that the Company and certain of its executives violated federal law. Specifically, the Law Offices of Howard G. Smith believes that the Company misled investors regarding its financial condition. More specifically, the Law Offices of Howard G. Smith believes that the Company misled investors by hiding that the Company’s only approved drug, Rezdiffra, was causing liver injury.

On November 3, 2026, Madrigal disclosed in its quarterly report on Form 10-Q that, on October 9, 2026, the Company’s former Senior Vice President, Head of Clinical Development Dr. Michael Charlton filed a Whistleblower complaint against the Company. The report states that, “Over the course of roughly eight months, Dr. Charlton repeatedly reported to Madrigal’s most senior executives, including directly to Chief Executive Officer Bill Sibold, and Chief Medical Officer David Soergel, that Madrigal was suppressing adverse liver-injury data, presenting efficacy results that could not be reconciled with their own source data, and allowing an unblinded Board member, former Chief Medical Officer and major shareholder to control the adjudication of clinical outcomes.” On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) prior to November 3, 2026 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.